Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

被引：0
|
作者：
Wei, Andrew
Strickland, Stephen A.
Roboz, Gail J.
Hou, Jing-Zhou
Fiedler, Walter
Lin, Tara L.
Walter, Roland B.
Enjeti, Anoop
Chyla, Brenda
Popovic, Relja
Fakouhi, Kaffa
Shah, Pooja
Dunbar, Martin
Xu, Tu
Mabry, Mack
Hayslip, John
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
890
引用
收藏
页数：4
相关论文
共 50 条
  • [1] UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAIVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ≥65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY
    Wei, A. H.
    Strickland, S. A.
    Roboz, G. J.
    Hou, J. -Z.
    Fiedler, W.
    Lin, T. L.
    Martinelli, G.
    Walter, R. B.
    Enjeti, A.
    Fakouhi, K. M.
    Darden, D. E.
    Dunbar, M.
    Xu, T.
    Mabry, M.
    Hayslip, J.
    HAEMATOLOGICA, 2017, 102 : 176 - 176
  • [2] PHASE 1B/2 STUDY OF VENETOCLAX WITH LOW-DOSE CYTARABINE IN TREATMENT-NAIVE PATIENTS AGED ≥65 YEARS WITH ACUTE MYELOGENOUS LEUKEMIA
    Lin, T. L.
    Strickland, S.
    Fiedler, W.
    Walter, R. B.
    Hou, J. Z.
    Roboz, G. J.
    Enjeti, A.
    Fakouhi, K. M.
    Darden, D. E.
    Dunbar, M.
    Zhu, M.
    Hayslip, J.
    Wei, A. H.
    HAEMATOLOGICA, 2016, 101 : 374 - 374
  • [3] Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥65 with acute myelogenous leukemia.
    Lin, Tara L.
    Strickland, Stephen Anthony
    Fiedler, Walter
    Walter, Roland B.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Enjeti, Anoop
    Fakhoui, Kaffa Mussumeh
    Darden, David E.
    Dunbar, Martin
    Zhu, Ming
    Hayslip, John W.
    Wei, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia
    Wei, Andrew
    Strickland, Stephen A.
    Roboz, Gail J.
    Hou, Jing-Zhou
    Fiedler, Walter
    Lin, Tara L.
    Martinelli, Giovanni
    Walter, Roland B.
    Enjeti, Anoop
    Fakouhi, Kaffa
    Darden, David E.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh
    Salem, Ahmed H.
    Mabry, Mack
    Hayslip, John
    BLOOD, 2016, 128 (22)
  • [5] Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
    Loges, Sonja
    Heuser, Michael
    Chromik, Joerg
    Sutamtewagul, Grerk
    Kapp-Schwoerer, Silke
    Crugnola, Monica
    Di Renzo, Nicola
    Lemoli, Roberto
    Mattei, Daniele
    Fiedler, Walter
    Alvarado-Valero, Yesid
    Ben-Batalla, Isabel
    Waizenegger, Jonas
    Rieckmann, Lisa-Marie
    Janning, Melanie
    Collienne, Maike
    Imbusch, Charles D.
    Beumer, Niklas
    Micklem, David
    Nilsson, Linn
    Madeleine, Noelly
    Mccracken, Nigel
    Oliva, Cristina
    Gorcea-Carson, Claudia
    Gjertsen, Bjorn T.
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [6] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Berdel, Andrew F.
    Koch, Raphael
    Gerss, Joachim
    Hentrich, Marcus
    Peceny, Rudolf
    Bartscht, Tobias
    Steffen, Bjoern
    Bischoff, Marina
    Spiekermann, Karsten
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Kewitz, Tobias
    Butterfass-Bahloul, Trude
    Serve, Hubert
    Lenz, Georg
    Berdel, Wolfgang E.
    Krug, Utz
    Schliemann, Christoph
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 63 - 72
  • [7] A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Andrew F. Berdel
    Raphael Koch
    Joachim Gerss
    Marcus Hentrich
    Rudolf Peceny
    Tobias Bartscht
    Björn Steffen
    Marina Bischoff
    Karsten Spiekermann
    Linus Angenendt
    Jan-Henrik Mikesch
    Tobias Kewitz
    Trude Butterfass-Bahloul
    Hubert Serve
    Georg Lenz
    Wolfgang E. Berdel
    Utz Krug
    Christoph Schliemann
    Annals of Hematology, 2023, 102 : 63 - 72
  • [8] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
  • [9] Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    Meng, Danchen
    Ruan, Min
    Liu, Xinyao
    Wu, Wei
    Zhuang, Junling
    Ge, Jian
    Huang, Zhenqi
    Long, Zhangbiao
    BLOOD, 2023, 142
  • [10] LOW-DOSE CYTARABINE VERSUS INTENSIVE CHEMOTHERAPY IN THE TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA IN THE ELDERLY
    TILLY, H
    CASTAIGNE, S
    BORDESSOULE, D
    CASASSUS, P
    LEPRISE, PY
    TERTIAN, G
    DESABLENS, B
    HENRYAMAR, M
    DEGOS, L
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 272 - 279
12345